Cargando…

Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains

PURPOSE: Cefmetazole (CMZ), a cephamycin antibiotic, is primarily used as a definitive therapy for Extended Spectrum β-Lactamase (ESBL)-producing Escherichia coli infections. However, the mechanism of CMZ resistance in E. coli is still unknown. To elucidate the resistance mechanism and to determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Ryota, Kawamura, Masato, Sato, Takumi, Fujimura, Shigeru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553235/
https://www.ncbi.nlm.nih.gov/pubmed/36237294
http://dx.doi.org/10.2147/IDR.S382142
_version_ 1784806423473946624
author Ito, Ryota
Kawamura, Masato
Sato, Takumi
Fujimura, Shigeru
author_facet Ito, Ryota
Kawamura, Masato
Sato, Takumi
Fujimura, Shigeru
author_sort Ito, Ryota
collection PubMed
description PURPOSE: Cefmetazole (CMZ), a cephamycin antibiotic, is primarily used as a definitive therapy for Extended Spectrum β-Lactamase (ESBL)-producing Escherichia coli infections. However, the mechanism of CMZ resistance in E. coli is still unknown. To elucidate the resistance mechanism and to determine combined drugs for prevention of resistance acquisition. METHODS: Clinical isolates of 14 ESBL-producing E. coli and non-producing 12 isolates were used in in vitro testing of CMZ resistance acquisition. After 10-day of CMZ exposure (1st subculture), these strains were incubated in an antibacterial-free medium for 14-day. These strains were again exposed to CMZ for 10-day (2nd subculture) and confirmed for changes in MIC. For each strain detected after 1st subculture, each mRNA expression level of porin, chromosomal ampC, and drug-efflux pump was measured using real-time RT-PCR. Relebactam (REL) has the potency to recover antimicrobial activity against carbapenem-resistant Enterobacterales that has porin deficiency. REL was added to the CMZ dilution series, and MIC changes and those of porin were confirmed. RESULTS: Of these 26 strains, 15 strains (57.7%) acquired resistance after 1st subculture, but after passage culture on the antibacterial-free medium, 11 strains recovered susceptibility. These 11 strains showed resistance after 2nd subculture. The expression levels of ompF and ompC were significantly decreased in these strains (P<0.05). When REL was added, all strains suppressed resistance acquisition after 1st subculture. The mechanism was the activation of ompF. CONCLUSION: Our results showed that the mRNA expression levels of genes encoding porin were decreased in the strains that acquired resistance due to CMZ exposure, and that ompF and ompC in particular were thought to be involved in the acquisition of resistance. The CMZ acquisition of resistance was also suppressed by the concomitant use of REL and actually suppressed the decrease in mRNA expression in ompF. It was confirmed that porin reactivated by REL.
format Online
Article
Text
id pubmed-9553235
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-95532352022-10-12 Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains Ito, Ryota Kawamura, Masato Sato, Takumi Fujimura, Shigeru Infect Drug Resist Original Research PURPOSE: Cefmetazole (CMZ), a cephamycin antibiotic, is primarily used as a definitive therapy for Extended Spectrum β-Lactamase (ESBL)-producing Escherichia coli infections. However, the mechanism of CMZ resistance in E. coli is still unknown. To elucidate the resistance mechanism and to determine combined drugs for prevention of resistance acquisition. METHODS: Clinical isolates of 14 ESBL-producing E. coli and non-producing 12 isolates were used in in vitro testing of CMZ resistance acquisition. After 10-day of CMZ exposure (1st subculture), these strains were incubated in an antibacterial-free medium for 14-day. These strains were again exposed to CMZ for 10-day (2nd subculture) and confirmed for changes in MIC. For each strain detected after 1st subculture, each mRNA expression level of porin, chromosomal ampC, and drug-efflux pump was measured using real-time RT-PCR. Relebactam (REL) has the potency to recover antimicrobial activity against carbapenem-resistant Enterobacterales that has porin deficiency. REL was added to the CMZ dilution series, and MIC changes and those of porin were confirmed. RESULTS: Of these 26 strains, 15 strains (57.7%) acquired resistance after 1st subculture, but after passage culture on the antibacterial-free medium, 11 strains recovered susceptibility. These 11 strains showed resistance after 2nd subculture. The expression levels of ompF and ompC were significantly decreased in these strains (P<0.05). When REL was added, all strains suppressed resistance acquisition after 1st subculture. The mechanism was the activation of ompF. CONCLUSION: Our results showed that the mRNA expression levels of genes encoding porin were decreased in the strains that acquired resistance due to CMZ exposure, and that ompF and ompC in particular were thought to be involved in the acquisition of resistance. The CMZ acquisition of resistance was also suppressed by the concomitant use of REL and actually suppressed the decrease in mRNA expression in ompF. It was confirmed that porin reactivated by REL. Dove 2022-10-10 /pmc/articles/PMC9553235/ /pubmed/36237294 http://dx.doi.org/10.2147/IDR.S382142 Text en © 2022 Ito et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ito, Ryota
Kawamura, Masato
Sato, Takumi
Fujimura, Shigeru
Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains
title Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains
title_full Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains
title_fullStr Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains
title_full_unstemmed Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains
title_short Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains
title_sort cefmetazole resistance mechanism for escherichia coli including esbl-producing strains
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553235/
https://www.ncbi.nlm.nih.gov/pubmed/36237294
http://dx.doi.org/10.2147/IDR.S382142
work_keys_str_mv AT itoryota cefmetazoleresistancemechanismforescherichiacoliincludingesblproducingstrains
AT kawamuramasato cefmetazoleresistancemechanismforescherichiacoliincludingesblproducingstrains
AT satotakumi cefmetazoleresistancemechanismforescherichiacoliincludingesblproducingstrains
AT fujimurashigeru cefmetazoleresistancemechanismforescherichiacoliincludingesblproducingstrains